GlobalData on MSN8h
Enrolment concludes in Zealand’s Phase IIb obesity therapy trialZealand Pharma has concluded enrolment for its global, randomised Phase IIb ZUPREME-1 trial, assessing the long-acting amylin analogue, petrelintide, in individuals with obesity or overweight and ...
With official shortages ended, but the first generics gearing up for launch, companies are looking for the next generation of ...
Sarepta Therapeutics (SRPT) stock drops 25% as the company reports a patient death linked to Elevidys, its gene therapy developed with Roche (RHHBY). Read more here.
Investor's Business Daily on MSN22h
Incyte Loses 9% As Skin Disease Drug Looks 'Viable, But Not Competitive'Incyte's skin disease treatment looks "viable, but not competitive with biologics," an analyst said Monday as Incyte stock fell.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback